Breast Cancer News

A research study, WISDOM, is currently underway to improve breast cancer diagnosis timing and outcomes by comparing annual mammography with a personalized screening approach to identify women at highest risk for fast-growing cancers.

The addition of inavolisib to palbociclib and fulvestrant more than doubled PFS for certain patients with advanced breast cancer, according to results of a randomized phase 3 trial.

Lack of health insurance contributes to a high percentage of racial and ethnic disparities in advanced-stage diagnoses for several cancer types, according to results of a mediation analysis.

Researchers reported beneficial effects of a supervised exercise intervention on breast cancer outcomes, according to preliminary findings from the OptiTrain trial presented at ESMO Congress.

Breast cancer survivors who participated in a remote personalized exercise program experienced modest improvements in quality of life, according to results from the eMouvoir trial presented at ESMO Congress.

A telephone-based weight loss intervention significantly increased moderate or vigorous physical activity in patients with breast cancer with overweight/obesity, according to a breast cancer weight loss trial presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

For many oncologists, the use of mastectomy to treat breast cancer cases can be a difficult subject to approach with patients.